Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Pinta

Internal Medicine Cuyahoga Falls, OH Medical Doctor

NPI 1023008752 CMS profile 91618

3239 State Rd, Cuyahoga Falls, OH 44223

Open in the dashboard

General payments

$14,096

946 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Pinta of Cuyahoga Falls, OH is reported in the CMS Open Payments database as having received $14,096 across 946 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,001 121
2024 General $2,321 155
2023 General $2,416 151
2022 General $2,515 166
2021 General $2,135 131
2020 General $1,066 81
2019 General $1,643 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Pinta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gary Pinta were reported at $2,001. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gary Pinta Internal Medicine median Middle half National median
2019 $1,643 $159 $48–$570 $163
2020 $1,066 $119 $33–$402 $114
2021 $2,135 $135 $37–$521 $132
2022 $2,515 $141 $42–$496 $149
2023 $2,416 $149 $45–$519 $160
2024 $2,321 $154 $47–$537 $164
2025 $2,001 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,196 137 payments
  2. Novo Nordisk Inc $1,624 129 payments
  3. Pfizer Inc. $1,247 88 payments
  4. GlaxoSmithKline, LLC. $1,198 104 payments
  5. Lilly USA, LLC $802 61 payments
  6. Astellas Pharma US Inc $742 30 payments
  7. AstraZeneca Pharmaceuticals LP $738 46 payments
  8. Amgen Inc. $599 38 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $522 28 payments
  10. Merck Sharp & Dohme Corporation $514 38 payments
  11. Other $3,913 247 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,848 936 payments
  2. Education $248 10 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,040 81 payments
  2. VRAYLAR $930 44 payments
  3. UBRELVY $802 61 payments
  4. RYBELSUS $734 56 payments
  5. NURTEC ODT $679 51 payments
  6. TRELEGY ELLIPTA $639 54 payments
  7. QULIPTA $535 42 payments
  8. Kerendia $522 28 payments
  9. COMIRNATY $451 28 payments
  10. ZAVZPRET $382 32 payments
  11. Other $13,281 914 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

11,538

Median for Internal Medicine: 777

Drug cost

$858,664

Median for Internal Medicine: $73,373

Branded share of claims

22.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 149 $171,714
Januvia Sitagliptin Phosphate Brand 69 $92,479
Ozempic Semaglutide Brand 87 $87,863
Jardiance Empagliflozin Brand 97 $82,373
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 52 $54,985
Farxiga Dapagliflozin Propanediol Brand 49 $48,932
Myrbetriq Mirabegron Brand 40 $29,044
Breo Ellipta Fluticasone/Vilanterol Brand 37 $28,882
Xarelto Rivaroxaban Brand 18 $28,875
Entresto Sacubitril/Valsartan Brand 13 $19,516

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$119,884

Of which drugs: $19,855

Medicare patients

224

Average age 75

Services billed

2,168

83 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 39%
COPD 29%
Ischemic heart disease 27%
Diabetes 25%
Atrial fibrillation 23%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 48 48 $13,854
Vaccine for influenza for injection into muscle 90653 Office 76 76 $5,962

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$165 — —
MOUNJARO
$129 14 —
TRELEGY ELLIPTA
$121 52 —
NURTEC ODT
$117 — —
JARDIANCE
$105 97 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

946 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record